WS016 not checked
Waterstone Pharmaceutical (Wuhan) Co., LTD.
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “WS016, oral, once daily for 11 months, starting at a dose of 12g with subsequent dose adjustments based on serum potassium levels.”In the company’s words, NCT07251309 on ClinicalTrials.gov
- Tested for
- Hyperkalemia (2 trials)
- Main trialPhase 3
- “This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.”In the company’s words, NCT07251309 on ClinicalTrials.gov
Other drugs for Hyperkalemia
- PatiromerVifor Pharma, Inc. · Relypsa, Inc. · Phase 2
- Sodium Zirconium CyclosilicateAstraZeneca · Marketed (Phase 4 trial)
Coming up2
- NovPhase 3 trial completes · ClinicalTrials.gov
- 20 Feb 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2026 | A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | |
| Phase 3Recruiting | 20 Feb 2029 | A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | |
| Phase 2Unknown | 18 Apr 2024 | A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. | |
| Phase 1Completed | 15 Jun 2023 | The Safety and Tolerability of WS016 in Healthy Chinese Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026